Therapeutic Pipeline

At Aurealcrat Inc., we have steadily deepened the science that underpins our computational discovery platform, strengthening its predictive power and expanding its reach across discovery and development. As these capabilities matured, our organization advanced in parallel—evolving from a tools-centric posture to an integrated, outcome-driven engine for therapeutic innovation.

To capture the full value of this platform for areas of significant unmet need, we established a dedicated therapeutics organization. Our pipeline embodies a disciplined, evidence-weighted approach that fuses physics-informed computation, AI-enabled modeling, and modern translational biology—advancing differentiated candidates with clear paths from hypothesis to the clinic.

Therapeutics Pipeline

Integrating physics-informed computation, AI, and translational biology to advance differentiated therapeutics.

Aurealcraft Ferroptosis Program Summary

Advancing next-generation therapies by harnessing ferroptosis to transform the fight against cancer and beyond.

AUR-ARF101 (GSR) — AUREXIS

Target: GSR (Glutathione Reductase)

Discovery

Small-molecule program aimed at selectively inducing ferroptosis in tumor cells by lowering the cellular GSH/NADPH buffer via GR inhibition, thereby reducing the lipid peroxidation threshold.

FerroptosisGR InhibitorOncology

AUR-ARF102 (GSR) — FERROVEXA

Target: GSR (Glutathione Reductase)

Lead Optimization

Series improving GR selectivity and cellular delivery through structure–activity relationships; validated by lipid peroxidation biomarkers and GSH/GSSG dynamics.

SARPK ProfileSelectivityBiomarker

AUR-ARF510 (GSR) — AUREXIS

Target: GSR (Glutathione Reductase)

Preclinical

Sub-program integrating pharmacodynamics and pharmacokinetics of GR-centered ferroptosis modulation to evaluate in vivo efficacy and the safety window in advanced candidates.

PD/PKIn vivoSafetyTranslational
© 2025 Aurealcrat Inc. All rights reserved.